About Immunofyx
Solid Tumour Therapy
ImmunoFyx is developing novel immuno-therapeutics to reduce the growth, angiogenesis, and metastasis of solid tumors. We specifically target and inhibit a highly expressed cell surface protease, over-expressed on more than 80% of all solid tumors, and engineer additional immune and non-immune mediated mechanisms of action into the same hybrid antibody to maximize efficacy.